Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her-2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT02453620
What this trial is testing

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+2 more
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Ended earlyNCT01151449
What this trial is testing

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast Cancer+7 more
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07459738
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Shanghai Henlius Biotech 60
Early research (Phase 1)Active Not RecruitingNCT04052555
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more
National Cancer Institute (NCI) 42
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Not applicableUnknownNCT05773391
What this trial is testing

Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure)

Who this might be right for
Breast Cancer
Sun Yat-sen University 100
Not applicableUnknownNCT06261918
What this trial is testing

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Who this might be right for
Breast CancerMetabolic Syndrome
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734290
What this trial is testing

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Providence Health & Services 29
Large-scale testing (Phase 3)Looking for participantsNCT07190443
What this trial is testing

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

Who this might be right for
Breast CancerLocoregional RecurrenceAbemaciclib+1 more
Japanese Foundation for Cancer Research 290
Large-scale testing (Phase 3)Study completedNCT02422615
What this trial is testing

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 726
Testing effectiveness (Phase 2)Looking for participantsNCT07540533
What this trial is testing

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Henan Cancer Hospital 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT02752685
What this trial is testing

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
NYU Langone Health 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT02311933
What this trial is testing

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7+3 more
National Cancer Institute (NCI) 81
Testing effectiveness (Phase 2)UnknownNCT05747326
What this trial is testing

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Not applicableLooking for participantsNCT04660435
What this trial is testing

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

Who this might be right for
Metastatic Breast CancerER Positive Breast CancerHER2-negative Breast Cancer
Fondazione Sandro Pitigliani 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05038735
What this trial is testing

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 210
Testing effectiveness (Phase 2)Looking for participantsNCT05872347
What this trial is testing

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Who this might be right for
Breast Cancer Brain Metastases
Shanghai Pharmaceuticals Holding Co., Ltd 52
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Next Page